+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 5 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the effects of aspirin and high-intensity statin therapy in people with severe coronary calcification, defined as a coronary calcium score of 300 or higher. The trial aims to understand how these treatments may help prevent atherosclerotic cardiovascular disease ASCVD events in this population. This phase 4, randomized, open-label trial uses a factorial design to assess both aspirin use and statin intensity. Participants are assigned to one of four groups aspirin 100 mgday with high-intensity statin therapy no aspirin with high-intensity statin therapy no aspirin with guideline-directed statin therapy or aspirin 100 mgday with guideline-directed statin therapy. Statin intensity follows the 2026 ACCAHA Guideline on the Management of Dyslipidemia. The study treatment lasts for 3 years, during which participants take the assigned medications. Throughout the trial, participants will be monitored for cardiovascular events and safety outcomes over 3 years. The main outcome is the rate of a composite of ASCVD events. Secondary outcomes include rates of individual cardiovascular events, death from any cause, hospitalization for heart failure, major bleeding, and safety endpoints. Participants will provide informed consent and follow the study protocol with scheduled clinical follow-ups to assess these outcomes.

Age: 40Years - 75YearsAll GendersPhase 4
32 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of Cellgram-LC, a biological treatment involving a single injection of autologous bone marrow-derived mesenchymal stem cells, in patients with alcoholic cirrhosis. This randomized, open-label Phase III trial compares Cellgram-LC with best supportive care BSC to determine if Cellgram-LC improves transplant-free survival and to identify any medical problems following treatment. Participants are assigned to one of two groups one group receives a single dose of Cellgram-LC through the hepatic artery at Week 0, and the other receives best supportive care. The study uses a parallel design with random allocation to these groups. Assessments occur at scheduled clinic visits at Week 4 and Months 3, 6, 9, 12, 18, and 24, along with telephone follow-ups at various months up to Month 36. During the study, participants undergo regular evaluations including liver function tests, fibrosis assessments, and quality of life questionnaires. Researchers measure transplant-free survival over three years as the primary outcome, along with survival rates, scores assessing liver function and fibrosis, and health status changes. The trial includes ongoing monitoring through clinic visits and telephone contacts, with total participation lasting up to 36 months.

Age: 20Years - 71YearsAll GendersPhase 3
15 locations
C

Actively Recruiting

Researchers are evaluating whether the risk of major adverse cardiac events over two years differs between two methods of guiding Percutaneous Coronary Intervention PCI in patients with Left Main Coronary Artery LMCA disease. The study compares Fractional Flow Reserve FFR-guided PCI and angiography-guided PCI to understand which approach may better influence treatment decisions and outcomes for this condition. Participants will be randomly assigned to receive either FFR-guided PCI or angiography-guided PCI. Both procedures involve using drug-eluting stents to treat significant LMCA disease and may include patients with other coronary artery diseases. The study will monitor participants for two years after their procedure, capturing various heart-related events and treatment outcomes during this period. During the two-year follow-up, participants will have clinical visits and assessments to track events such as death, heart attacks, hospitalizations, repeat procedures, stroke, bleeding, and stent problems. Researchers will also evaluate hospital stay length, procedure details, heart function, quality of life related to angina and health, and medication use. The study aims to provide comprehensive information on the safety and effectiveness of both PCI guidance strategies over this time frame.

Age: 20Years +All GendersPhase Not Applicable
49 locations
L

Actively Recruiting

This observational study focuses on patients with alcoholic liver cirrhosis who previously received Cellgram-LC treatment in the PMC-P-07 clinical trial. It aims to learn about the long-term safety of Cellgram-LC by monitoring key outcomes such as adverse events of special interest AESI and the occurrence of liver transplantation over five years following treatment. Participants who took part in the earlier PMC-P-07 study and received Cellgram-LC will be invited to join this follow-up study. The study involves annual telephone visits over a five-year period after the initial Cellgram-LC administration to collect information on any AESI or liver transplantation events. During the study, participants will be contacted by phone once a year to report health status related to AESI and liver transplantation. The research team will assess these outcomes annually to understand the long-term safety profile of Cellgram-LC. This follow-up period lasts five years from the date of Cellgram-LC administration, allowing close monitoring of participants health over time.

Age: 19Years - 70YearsAll Genders
14 locations
C

Actively Recruiting

Researchers are evaluating the best low-density lipoprotein LDL cholesterol targets for adults who have had a small vessel occlusion SVO stroke, a subtype of ischemic stroke. This trial addresses the lack of specific guidelines for LDL cholesterol levels tailored to different types of stroke, focusing on secondary prevention to reduce the risk of future cardiovascular events in patients with SVO stroke. The study is a multicenter, prospective, randomized, open, blinded-endpoint clinical trial led by Seoul National University Hospital. Participants will be randomly assigned to one of two groups aiming for different LDL cholesterol targets an intensive group targeting LDL cholesterol below 70 mgdL and a standard group targeting LDL cholesterol between 90 and 110 mgdL. Both groups will receive lipid-lowering medications including statins andor ezetimibe, and PCSK9 inhibitors may be used if LDL targets are not reached with initial therapies. The trial plans to enroll 4,016 adults with confirmed SVO stroke within 180 days before randomization. During the study, participants will be monitored for major adverse cardiovascular events such as cardiovascular death, stroke, and acute coronary syndrome over a follow-up period of at least four years. Researchers will assess various outcomes including any stroke, ischemic stroke or transient ischemic attack, myocardial infarction, and hemorrhagic stroke. Participants will undergo regular evaluations to measure LDL cholesterol levels and cardiovascular health, with safety and adherence closely monitored throughout the trial duration.

Age: 19Years +All GendersPhase Not Applicable
46 locations